What is Neurosteer?
Neurosteer is a pioneering medical technology firm that has engineered a pocket-sized, medical-grade brain activity interpretation platform known as hdrEEG. By transforming complex neurological data into actionable insights, the company aims to revolutionize how clinicians approach brain scanning and monitoring. The platform is specifically designed to facilitate the early detection of cognitive decline and chronic neurological conditions, such as Parkinson's, Alzheimer's, and epilepsy. By providing real-time analysis and objective biomarkers, Neurosteer bridges the gap between traditional, cumbersome diagnostic equipment and the need for continuous, accessible remote monitoring. This innovation is poised to establish a new standard in brain health diagnostics, offering a more affordable and effective pathway for patient care and long-term neurological management.
How much funding has Neurosteer raised?
Neurosteer has raised a total of $44K across 1 funding round:
Debt
$44K
Debt (2021): $44K with participation from PPP
Key Investors in Neurosteer
PPP
Public-Private Partnership
What's next for Neurosteer?
With this latest round of financing, Neurosteer is well-positioned to accelerate its commercialization strategy and deepen its clinical footprint. The company is expected to focus on expanding its diagnostic capabilities, potentially integrating its hdrEEG technology into broader telehealth and remote patient monitoring frameworks. As the firm matures, the strategic deployment of this capital will likely prioritize regulatory milestones and the scaling of its manufacturing processes to meet the rising demand for objective, data-driven neurological assessments. By focusing on both clinical utility and patient accessibility, Neurosteer is set to play a critical role in the future of personalized brain health, moving toward a model where early intervention becomes the standard of care for neurodegenerative disorders.
See full Neurosteer company page
